Elevated plasma levels of apelin in children with type 1 diabetes mellitus

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 5, 2010, Pages 497-502

  Meral, Cihan ^a   Tascilar, Emre ^a   Karademir, Ferhan ^a   Tanju, Ilhan Asya ^a   Cekmez, Ferhat ^a   Ipcioglu, Osman Metin ^a   Ercin, Cemal Nuri ^b   Gocmen, Ismail ^a   Dogru, Teoman ^b  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Adiponectin; Apelin; Type 1 diabetes mellitus

Indexed keywords

ADIPONECTIN; APELIN; HEMOGLOBIN A1C; LIPID;

ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; PRESCHOOL CHILD; SCHOOL CHILD;

EID: 77954468480     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.2010.081     Document Type: Article

References (39)

1. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-476.
2. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004;118:119-125. (Pubitemid 38296725)
3. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, O'Dowd BF. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000;74:34-41. (Pubitemid 30012752)
4. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpene C, Audigier Y, Saulnier-Blache JS, Valet P. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146:1764-1771.
5. Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Gene H, Acikel C, Ozgurtas T, Sonmez A. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 2009;204:222-228.
6. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116:289-292. (Pubitemid 351798738)
7. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 1982;31:795-801. (Pubitemid 12062869)
8. Pang TT, Narendran P. Addressing insulin resistance in Type 1 diabetes. Diabet Med 2008;25:1015-1024.
9. Bonadonna RC, Groop L, Kraemer N, Ferrannini E, Del Prato S, DeFronzo RA. Obesity and insulin resistance in humans: a dose-response study. Metabolism 1990;39:452-459.
10. Caprio S, Branson M, Sherwin RS, Rife F, Tamborlane WV. Co-existence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children. Diabetologia 1996;39:1489-1497. (Pubitemid 26397355)
11. Sinaiko AR, Jacobs DR, Jr., Steinberger J, Moran A, Luepker R, Rocchini AP, Prineas RJ. Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. J Pediatr 2001;139:700-707. (Pubitemid 33097437)
12. Waldhor T, Schober E, Rami B. Regional distribution of risk for childhood diabetes in Austria and possible association with body mass index. Eur J Pediatr 2003;162:380-384. (Pubitemid 36693737)
13. Kibirige M, Metcalf B, Renuka R, Wilkin TJ. Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 2003;26:2865-2870.
14. Baum JD, Ounsted M, Smith MA. Letter: Weight gain in infancy and subsequent development of diabetes mellitus in childhood. Lancet 1975;2:866.
15. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 2001;44:914-922.
16. The American Diabetes Association (ADA) has been actively involved in the development and dissemination of diabetes care standards, guidelines, and related documents for many years. Introduction. Diabetes Care 2009;32 Suppl 1:S1-S2.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Masri B, Morin N, Pedebemade L, Knibiehler B, Audigier Y. The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. J Biol Chem 2006;281:18317-18326. (Pubitemid 44035488)
19. Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E, Alhava E, Akerman K, Herzig KH. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005;130:7-13. (Pubitemid 40966016)
20. Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, Bingol N, Kilic S, Bingol S, Erikci S. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 2007;115:428-432. (Pubitemid 47234642)
21. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002;18:192-200.
22. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661-1667. (Pubitemid 40022398)
23. McCarthy HD, Ellis SM, Cole TJ. Central overweight and obesity in British youth aged 11-16 years: cross sectional surveys of waist circumference. BMJ 2003;326:624.
24. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689. (Pubitemid 32893993)
25. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006;8:355-360.
26. Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, Friis-Hansen L. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 2006;133:134-138. (Pubitemid 41820346)
27. Codognotto M, Piccoli A, Zaninotto M, Mion M, Vertolli U, Tona F, Boffa GM. Evidence for decreased circulating apelin beyond heart involvement in uremic cardiomyopathy. Am J Nephrol 2007;27:1-6. (Pubitemid 46364534)
28. Celi F, Bini V, Papi F, Santilli E, Castellani MS, Ferretti A, Mencacci M, Berioli MG, De Giorgi G, Falomi A. Circulating adipocytokines in non-diabetic and Type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development. Diabet Med 2006;23:660-665.
29. Galler A, Gelbrich G, Kratzsch J, Noack N, Kapellen T, Kiess W. Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study. Eur J Endocrinol 2007;157:481-489.
30. Matsuzawa Y. Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005;6:7-14. (Pubitemid 40501304)
31. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007;76:24-29.
32. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006;110:267-278. (Pubitemid 43341630)
33. Cesari M, Pessina AC, Zanchetta M, De Toni R, Avogaro A, Pedon L, Dorigatti F, Maiolino G, Rossi GP. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. J Intern Med 2006;260:474-483.
34. Heliovaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P. Improved glycaemia in type 1 diabetes results in decreased levels of soluble adhesion molecules with no change in serum adiponectin or most acute phase proteins. Exp Clin Endocrinol Diabetes 2006;114:295-300.
35. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, Sayama K, Uno S, Iwahashi H, Yamagata K, Miyagawa J, Matsuzawa Y. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002;25:1665-1666.
36. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005;48:1911-1918. (Pubitemid 41317848)
37. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006;91:129-135.
38. Malyszko J, Malyszko JS, Brzosko S, Wolczynski S, Mysliwiec M. Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004;89:4620-4627.
39. Delaigle AM, Jonas JC, Bauche IB, Cornu O, Brichard SM. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 2004;145:5589-5597.